Treatment
Semaglutide clinical trials
We’re tracking 138 recruiting studies that include Semaglutide, each written for real people, not researchers, below.
Recruiting studies
- NCT07801820RecruitingPhase 2
Oral diabetes medication study
This study tests an investigational pill for people with type 2 diabetes whose blood sugar is not well controlled despite lifestyle changes or metformin. The pill may help improve blood sugar control and is taken by mouth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07779343Recruiting
Multidisciplinary support for adults living with obesity
This study tests a programme that combines medical, dietary, and behavioural support to help adults with obesity lose weight and improve their health. It looks at how well the programme works in everyday clinic settings.
AlgiersAges 18–65 - NCT07767175RecruitingPhase 1
Weight loss study for adults with overweight or obesity
This study tests an investigational medication, called NNC0721-8060, to see how it works in people with excess weight (overweight or obesity). It may help with weight loss, but is still in early human testing.
Lenexa, KansasAges 18–55 - NCT07743983RecruitingPhase 3
Study of BGM0504 in Early Type 2 Diabetes with Obesity
This trial tests an investigational drug, BGM0504, for people recently diagnosed with type 2 diabetes who also have obesity. It aims to see if the drug can help control blood sugar and support weight loss.
Nanjing, JiangsuAges 18–75 - NCT07745504RecruitingPhase 3
Comparing two versions of a new weight-loss medication
This study compares two different versions of an investigational weight-loss medication (cagrilintide) against a placebo to see which is more effective and safe for people with excess weight. Participation involves receiving injections and regular check-ins to monitor your progress.
Conyers, GeorgiaAges 18 years+ - NCT06318442Recruiting
Preventing steroid-induced diabetes with a GLP-1 drug
This study tests whether a GLP-1 medication (a type of drug that helps control blood sugar) can prevent diabetes caused by steroid treatments. It is for people who have prediabetes or mild diabetes and are about to receive a short course of steroids.
LondonAges 18 years+ - NCT07695454Recruiting
Imaging study of semaglutide for type 2 diabetes
This study uses special MRI scans to see how the diabetes medication semaglutide affects muscles and fat. If you are starting semaglutide for type 2 diabetes, this research may help doctors understand how the medicine works.
Cleveland, OhioAges 45–75 - NCT07677995Enrolling by invitation
Fatty acids and type 2 diabetes study
This study looks at how free fatty acids affect people with type 2 diabetes or pre-diabetes. You may be able to join if you are overweight, have high blood sugar, and are not on certain diabetes medications.
Coleraine, County LondonderryAges 18 years+ - NCT07653477RecruitingPhase 3
New diabetes drug for type 2 diabetes not well controlled with metformin
This trial tests an investigational drug called UBT251 for people with type 2 diabetes whose blood sugar is not well controlled despite taking metformin, either alone or with another diabetes medicine. The goal is to see if it can lower blood sugar levels more than a placebo.
ShanghaiAges 18–75 - NCT07653412Recruiting
Genetic test for predicting weight loss drug response
This trial looks at whether your genes can predict how well you will respond to weight loss medications like semaglutide (Wegovy/Ozempic) or tirzepatide (Mounjaro). It may help doctors choose the right drug for you based on your DNA.
AthensAges 18 years+ - NCT07633639Recruiting
GLP-1 Medicine After Weight-Loss Surgery in Chinese Patients
This trial tests whether adding a GLP-1 medication (a type of diabetes and weight-loss drug) after weight-loss surgery helps patients with obesity and related health conditions like diabetes. Researchers want to see if combining surgery with this medicine works better than surgery alone.
BeijingAges 18–60 - NCT07627191RecruitingEarly Phase 1
GLP-1 drug plus standard chemo for first-line advanced cancers
This trial tests whether adding a GLP-1 receptor agonist (a drug used for diabetes and weight loss) to standard chemotherapy can help people with advanced pancreatic, colorectal, or liver cancer. It is for people who have not yet started treatment for their metastatic disease and have a BMI of 25 or higher.
Tucson, ArizonaAges 18–99 - NCT07597018RecruitingPhase 1
Comparing Blood Levels of Cagrilintide Versions in Adults With Overweight
This early-stage study tests different formulations of cagrilintide, a new medication, to see how the body absorbs and processes each version. Cagrilintide may help with weight management. Researchers will measure blood levels after you receive multiple doses.
BerlinAges 18–64 - NCT07589322Recruiting
How GLP-1 drugs reshape fat and metabolism
This study compares how a GLP-1 medication (a drug that helps control blood sugar and weight) changes the way your body stores and uses fat. Researchers will use imaging scans to see these changes over time in people with metabolic syndrome—a cluster of health conditions including high blood pressure, high cholesterol, and excess weight.
TaipeiAges 20–65 - NCT07563699RecruitingPhase 1/Phase 2
Long-acting semaglutide injection for type 2 diabetes
This study tests a new long-acting form of semaglutide (a diabetes medication you may already take weekly) given as a depot injection. Researchers want to see if this new form is safe and works better for managing type 2 diabetes.
Tel AvivAges 18–64 - NCT07547878Enrolling by invitationPhase 4
Starting four kidney-protective medicines together for type 2 diabetes
This study looks at whether starting four recommended medications all at once—instead of one by one—is safe and better for protecting the kidneys in people with type 2 diabetes and early kidney damage. You would receive all four medicines together and be closely monitored by the study team.
Temple, TexasAges 18–84 - NCT06082063RecruitingPhase 3
Reducing heart disease risk in type 1 diabetes
This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.
CopenhagenAges 40–90 - NCT07456774Enrolling by invitation
How long do people stay on Ozempic for diabetes (China study)
This study looks at how well people in China stick with taking Ozempic (a once-weekly injection) compared to other diabetes medicines. It helps researchers understand if this medicine is easier to keep taking long-term.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07428746RecruitingPhase 3
GLP-1 drug for bone health in older women with diabetes
This study tests whether a diabetes medication called a GLP-1 receptor agonist can help improve bone and muscle health in older women with type 2 diabetes who are at risk for osteoporosis. It aims to see if the drug can strengthen bones and prevent falls.
Atlanta, GeorgiaAges 65 years+ - NCT07415954RecruitingPhase 2
Testing a new diabetes medicine for blood sugar control
This study tests a new medicine, NNC0662-0419, in people with type 2 diabetes. You must be willing to lose a lot of weight (more than a quarter of your current weight) as part of the study to see if the medicine helps lower blood sugar.
Lancaster, CaliforniaAges 18–75 - NCT07374328RecruitingPhase 1/Phase 2
Three diabetes medicines for new type 2 diabetes
This trial tests a combination of three diabetes medicines to see if they can quickly get high blood sugar under control in people newly diagnosed with type 2 diabetes. It's designed for those whose HbA1c is 9.0% or higher.
Guangzhou, GuangdongAges 18–65 - NCT05501483Recruiting
Study how fat differences may relate to type 2 diabetes
This study looks at differences in body fat to understand why some people develop type 2 diabetes. You may be asked for blood tests and health information to see if your diabetes risk and body fat patterns are linked.
StockholmAges 30–70 - NCT07314684RecruitingPhase 4
Semaglutide's effect on inflammation in type 2 diabetes
This study tests whether the diabetes medication semaglutide can reduce inflammation and improve blood vessel health in people with type 2 diabetes who have no significant heart artery blockages. If you have diabetes and are at moderate to high heart risk but haven't had heart problems, this could help understand the medicine's extra benefits beyond blood sugar control.
Caserta, CasertaAges 18–85 - NCT07297589RecruitingPhase 3
CT scan of heart fat after heart attack
This study uses a CT scan to look at the layer of fat around the heart in people who recently had a heart attack and have type 2 diabetes and obesity. It aims to understand how this fat relates to inflammation and heart health.
León, GuanajuatoAges 18 years+
Common questions
- Are there clinical trials studying Semaglutide?
- Yes. Clin2 currently lists 138 recruiting studies that include Semaglutide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Semaglutide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Semaglutide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Semaglutide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.